ERBB3 and ovarian carcinoma: Jacobsen et al[31] and Li et al[32] have found that the expression of Her3 increased in breast cancer resistant cell lines (MDA-MB-175-VII) and ovarian cancer drug-resistant cell lines (SKOV3-T) after trastuzumab treatment.